

## Nanexa receives decision on sanction fee from Finansinspektionen regarding case from 2017

**Nanexa AB today announces that the company has received a decision from Finansinspektionen (Sweden's financial supervisory authority) to pay a penalty fee of SEK 1,000,000 regarding events that occurred in 2017.**

Finansinspektionen has found that Nanexa, in connection with decision regarding a rights issue in September 2017, has disregarded the requirements for publication of insider information and preparation of a correct insider list in Regulation (EU) 596/2014 of the European Parliament and of the Council on market abuse (market abuse regulation).

A total fee of SEK 1,100,000 has been reduced to SEK 1,000,000 in a proportionality assessment and after Finansinspektionen has established that there has been an unreasonable delay in the handling of the case.

### **For additional information, please contact:**

---

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: [david.westberg@nanexa.se](mailto:david.westberg@nanexa.se)

[www.nanexa.com](http://www.nanexa.com)

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

### **About Nanexa AB (publ)**

---

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

### **Attachments**

---

[Nanexa receives decision on sanction fee from Finansinspektionen regarding case from 2017](#)